darunavir sandoz 800 mg tabletki powlekane
sandoz gmbh - darunavirum - tabletki powlekane - 800 mg
bortezomib pharmaswiss 3,5 mg proszek do sporządzania roztworu do wstrzykiwań
pharmaswiss Česká republika s.r.o. - bortezomibum - proszek do sporządzania roztworu do wstrzykiwań - 3,5 mg
darunavir sandoz 150 mg tabletki powlekane
sandoz gmbh - darunavirum - tabletki powlekane - 150 mg
tigecycline sandoz 50 mg proszek do sporządzania roztworu do infuzji
sandoz gmbh - tigecyclinum - proszek do sporządzania roztworu do infuzji - 50 mg
unbremi 25 mg tabletki powlekane
aflofarm farmacja polska sp. z o.o. - agomelatyna - tabletki powlekane - 25 mg
agodeprin 25 mg tabletka powlekana
sandoz gmbh - agomelatinum - tabletka powlekana - 25 mg
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroksysmal - selektywne leki immunosupresyjne - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
rhokiinsa
santen oy - netarsudil - glaucoma, open-angle; ocular hypertension - okulistyka - obniżenie podwyższonego ciśnienia wewnątrzgałkowego (iop) u dorosłych pacjentów z pierwotną jaskrą otwartego kąta lub nadciśnienie oczne.
lumeblue (previously known as methylthioninium chloride cosmo)
alfasigma s.p.a. - chlorek metylotioniny - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.
fingolimod alvogen 0,5 mg kapsułki twarde
zentiva, k.s. - fingolimodum - kapsułki twarde - 0,5 mg